These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 834124)

  • 1. FDA considerations regarding new hypolipidemic agents.
    Finkel MJ
    Lipids; 1977 Jan; 12(1):64-5. PubMed ID: 834124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antilipemic drugs and the position of the FDA.
    Finkel MJ
    Adv Exp Med Biol; 1972; 26(0):263-5. PubMed ID: 4679645
    [No Abstract]   [Full Text] [Related]  

  • 3. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
    Carpenter D
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
    Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
    J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U.S. biomedical policy. NCI head to fill in at FDA after Crawford resignation.
    Couzin J; Kaiser J
    Science; 2005 Sep; 309(5744):2142-3. PubMed ID: 16195428
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing safety, effectiveness, and public desire: the FDA and cancer.
    Conti R
    Issue Brief (Commonw Fund); 2003 Apr; (615):1-6. PubMed ID: 12693391
    [No Abstract]   [Full Text] [Related]  

  • 7. U.S. science policy. Cancer institute director tapped for FDA.
    Kaiser J; Couzin J
    Science; 2006 Mar; 311(5768):1692. PubMed ID: 16556808
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
    Deak D; Outterson K; Powers JH; Kesselheim AS
    Ann Intern Med; 2016 Sep; 165(5):363-72. PubMed ID: 27239977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
    Steinvil A; Rogers T; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1757-64. PubMed ID: 27609249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. biomedical policy. Acting FDA head drops NCI post.
    Kaiser J
    Science; 2005 Oct; 310(5745):29. PubMed ID: 16210502
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 12. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
    Califf RM; Kramer JM
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
    [No Abstract]   [Full Text] [Related]  

  • 13. Memorandum of understanding between the Food and Drug Administration and the National Institutes of Health's National Institute of Dental Research--FDA. Notice.
    Fed Regist; 1998 Jun; 63(105):30002-5. PubMed ID: 10180274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in complementary and alternative medicine: contribution of the National Institutes of Health and the Food and Drug Administration.
    Eskinazi D; Hoffman FA
    J Altern Complement Med; 1998; 4(4):459-67. PubMed ID: 9884181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.
    Weinreb RN; Kaufman PL
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1497-505. PubMed ID: 19321793
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA follows NIH in review of staff consulting activities.
    Ault A
    Lancet; 2004 May; 363(9423):1779. PubMed ID: 15174475
    [No Abstract]   [Full Text] [Related]  

  • 18. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 19. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    Psaty BM; Lumley T
    JAMA; 2008 Mar; 299(12):1474-6. PubMed ID: 18364491
    [No Abstract]   [Full Text] [Related]  

  • 20. NCI, FDA to collaborate on speeding up drug discovery.
    Arnold K
    J Natl Cancer Inst; 2003 Aug; 95(16):1192. PubMed ID: 12928341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.